HBM Holdings Limited
HKEX:2142.HK
1.19 (HKD) • At close November 13, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | HBM Holdings Limited |
Symbool | 2142.HK |
Munteenheid | HKD |
Prijs | 1.19 |
Beurswaarde | 914,962,440 |
Dividendpercentage | 0% |
52-weken bereik | 1.01 - 1.98 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Jingsong Wang M.D., Ph.D. |
Website | https://www.harbourbiomed.com |
An error occurred while fetching data.
Over HBM Holdings Limited
HBM Holdings Limited, a clinical-stage biopharmaceutical company, engages in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. It is developing Batoclimab (HBM9161), a human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor; Tanfanercept (HBM9036) to treat moderate to-severe dry
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (HKD)
Cijfers zijn in miljoenen (HKD)